IKT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain...

Stats
Today's Volume	45 224.00
Average Volume	64 693.00
Market Cap	11.20M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.790 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0300 (1.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Werner Milton H.	Buy	45 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Buy	90 000	Stock Option (right to buy)
2024-04-01	Lees-rolfe Garth	Sell	5 834	Stock Option (right to buy)
2023-06-30	Berman Dennis N	Buy	6 667	Stock Option (right to buy)
2023-06-30	Dion Gisele	Buy	6 667	Stock Option (right to buy)

INSIDER POWER
96.38
Last 62 transactions
Buy: 1 923 769 \| Sell: 2 120 717

Volume Correlation

Long: -0.05 (neutral)

Short: 0.08 (neutral)

Signal:(40.402) Neutral

Inhibikase Therapeutics, Correlation

10 Most Positive Correlations
ECOR	0.835
CPLP	0.833
SVOK	0.82
CLST	0.816
PROV	0.815
BHFAO	0.815
CFBK	0.815
MREO	0.811
OCCIO	0.809
HMST	0.806

10 Most Negative Correlations
OSMT	-0.843
IQ	-0.829
VISL	-0.821

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Inhibikase Therapeutics, Correlation - Currency/Commodity

-0.39
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.50
( neutral )

0.01
( neutral )

Inhibikase Therapeutics, Financials

Annual	2023
Revenue:	$260 500
Gross Profit:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2023
Revenue:	$260 500
Gross Profit:	$83 102.00 (31.90 %)
EPS:	$-3.57

FY	2022
Revenue:	$123 440
Gross Profit:	$116 717 (94.55 %)
EPS:	$-4.26

FY	2021
Revenue:	$3.10M
Gross Profit:	$3.10M (100.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Inhibikase Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Inhibikase Therapeutics,

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Realtime updates for Inhibikase Therapeutics, [IKT]

Upcoming Earnings Alert

Inhibikase Therapeutics, Options Data

Calls

Puts